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Maastricht University, Maastricht, Limburg, The Netherlands; 2 Health Care Insurance Board (CVZ), Diemen, The Netherlands; 3 University Maastricht & Erasmus University Rotterdam, Maastricht, The Netherlands BACKGROUND: In Western jurisdictions, coverage with evidence development (CED) is seen as a promising scheme for linking coverage decisions on innovative health technologies with the generation of additional evidence. Nonetheless, the implementation of such CED schemes is not guaranteed to be successful, with issues arising around both evidence generation and (dis)continued coverage of technologies. OBJECTIVES: This qualitative study aims to explore the practical experiences with CED schemes for technology coverage. METHODS: Semi-structured interviews were conducted with key stakeholders involved in the decision making process about reimbursement of health technologies in Australia, Belgium, Ontario (Canada), France, Germany, Galicia (Spain), Sweden, UK and USA. The questionnaire for the interview was developed on the basis of comprehensive literature review and expert opinion, addressing issues related to the aim of CED, initial assessment/appraisal, evidence development, re-assessment/reappraisal and coverage for technologies. RESULTS: CED schemes vary widely in the evidence generation, time frame, the regulation and funding of research, and the involvement of stakeholders in the CED process. This variation is caused by the structure and fi nancing of health services delivery, the aim of CED, and the type of health technology. The CED process is often non-transparent, particularly relating to the selection of technologies and the re-assessment/re-appraisal for coverage (dis)continuation. (Dis) continued coverage of technologies is often primarily driven by the pressures from patients, health professional and health institutions to provide access to innovative technologies or public opinion. CONCLUSIONS: The successful implementation of CED schemes requires: a) a transparent (analytic) framework for the selection of health technologies and the generation of additional evidence; b) a clear legal authority to regulate evidence generation, time frame and research budget; c) a structural involvement of stakeholders in the process of CED; and d) a priori clear end points for the re-assessment/ re-appraisal and technology coverage.
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PHP87 THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH CARE RESEARCH PRIORITY SETTING: A THEORETICAL CASE STUDY
Corro Ramos I, Rutten-van Mölken MP, Al MJ Erasmus University, Rotterdam, The Netherlands BACKGROUND: The Dutch reimbursement procedure for expensive hospital drugs requires the submission of a baseline cost-effectiveness analysis together with a research plan for the period of temporary reimbursement in order to estimate the real-life cost-effectiveness after 4 years. In this situation, a Value-of-Information (VOI) analysis might identify the critical parameters that need to be studied in such outcome study. OBJECTIVES: To identify when a VOI analysis alongside sensitivity analyses is warranted, and when such VOI analysis will not impact the decision making process. METHODS: We used a hypothetical Markov model with three groups of parameters: costs, utilities and transition probabilities. We studied different confi gurations of input parameters, forcing the outcomes into different directions on the CE-plane. For each input confi guration we performed a multivariate sensitivity analysis (MSA) and a probabilistic sensitivity analysis (PSA). In the MSA, sensitivity was measured as percentage change from baseline INMB. Additionally, we analyzed the expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPI). Analyses were done for a range of threshold ICERs. RESULTS: For each situation it was possible to predict the shape (but not the absolute value) of the EVPI curve based on the PSA fi ndings. When the PSA plot covered both northern quadrants, MSA and EVPPI came to the same ranking of the groups of parameters. When the outcomes were in the northeast quadrant the ranking differed: MSA indicated costs as most important parameters, for EVPPI this was utilities. When outcomes where in the southwest quadrant, costs were most important in MSA and EVPPI. For both other quadrants, MSA and EVPPI were close to zero for all groups. CONCLUSIONS: Whether MSA and EVPPI come to a different priority setting for future research depends both on the threshold ICER and on the location of results on the CE-plane.
PHP88 STAKEHOLDER PERCEPTIONS OF CLINICAL DRUG TRIALS
University of Tasmania/Manukau Institute of Technology, Auckland, New Zealand; 2 University of Tasmania, Hobart, Australia OBJECTIVES: To identify stakeholder perceptions of sponsored clinical trials in a publically funded New Zealand hospital, and then to identify the similarities and differences in perceptions across these stakeholder groups. The stakeholders are: 1) participants involved in clinical trials; 2) management and the multidisciplinary team; 3) the larger South Auckland community; 4) government and decision makers; and 5) the pharmaceutical industry. METHODS: We use purposive sampling to select representatives of the stakeholder groups, which provides 109 respondents. We gather data using focus groups, in-depth interviews, telephone interviews and surveys. RESULTS: Many of the respondents represent more than one stakeholder group. While there is consensus across the stakeholders on some costs and benefi ts such as developing safe medicines and collecting useful data there are marked differences in perceptions in other areas, such as those indicated below. Most stakeholders perceive the risk of adverse reactions as the greatest cost to trial participants but the participants themselves do not regard this as signifi cant. Pharmaceutical representatives, management and the multidisciplinary team feel that gaining access to new medicines motivates people to participate in a trial. Trial participants feel that the support is more important to them than the medication. Most researchers and staff believe trial involvement increases their job satisfaction, motivation, knowledge and skills while a few have concerns that sponsor control leads to the loss of their fl exibility and independence Generally there is a perception that New Zealand based clinical trials assist in the process of obtaining registration and subsidization of new drugs in New Zealand. However, this perception may be erroneous as location of trials is apparently not considered in the drug registration process. CONCLUSIONS: We fi nd that most stakeholders are satisfi ed with the conduct of clinical trials in New Zealand and they believe the benefi ts outweigh the costs.
PHP89 PERCEPTION OF PHARMACO-EPIDEMIOLOGICAL STUDIES BY PHYSICIANS AND MOTIVATION TO PARTICIPATE: FRENCH SITUATION
Schmidely N 1 , Bonhomme C 1 , Veysseyre H 2 , Nechadi S 2 , Longin J 2 1 Bristol-Myers Squibb, Rueil Malmaison, France; 2 REGISTRAT-MAPI, Lyon, France OBJECTIVES: Recent development of Health Technology Assessment worldwide increased requirement for real world data (e,g, risk management plans, drugs utilization). Primary non-interventional research (NIR) involving physicians able to enrol patients is a means to generate such data. One key challenge of NIRs is the capacity to refl ect real life conditions by providing unbiased estimations of physicians' behaviours and patients outcomes in large representative samples. Participation of physicians is often an issue when conducting NIRs. Lack of understanding of scientifi c value of NIRs, compared to clinical trials, is often assumed to be the major reason for reluctance to participate. Our objective was to better understand perception of, motivation to participate in and expectation from participation in NIRs by physicians.
